iloprost and 13-14-didehydro-20-methylcarboprostacyclin

iloprost has been researched along with 13-14-didehydro-20-methylcarboprostacyclin* in 1 studies

Other Studies

1 other study(ies) available for iloprost and 13-14-didehydro-20-methylcarboprostacyclin

Article	Year
The putative prostacyclin receptor antagonist (FCE-22176) is a full agonist on human platelets and NCB-20 cells. European journal of pharmacology, 1986, Aug-07, Volume: 127, Issue:1-2 The action of FCE-22176 on prostacyclin receptors of human platelets and the NCB-20 cell line have been examined. FCE-22176 is a full agonist in both systems, mediating activation of adenylate cyclase. The concentration required for half-maximum enzyme activation was 174 nM in platelet membranes and 193 nM in homogenates of NCB-20 cells. The binding of [3H]iloprost to human platelet or NCB-20 cell membranes was inhibited by FCE-22176, and Ki values of 400 and 280 nM were obtained. Topics: Adenylyl Cyclases; Blood Platelets; Cell Line; Cell Membrane; Enzyme Activation; Epoprostenol; Humans; Iloprost; In Vitro Techniques; Receptors, Epoprostenol; Receptors, Prostaglandin	1986

Article

Year

The putative prostacyclin receptor antagonist (FCE-22176) is a full agonist on human platelets and NCB-20 cells.

European journal of pharmacology, 1986, Aug-07, Volume: 127, Issue:1-2

The action of FCE-22176 on prostacyclin receptors of human platelets and the NCB-20 cell line have been examined. FCE-22176 is a full agonist in both systems, mediating activation of adenylate cyclase. The concentration required for half-maximum enzyme activation was 174 nM in platelet membranes and 193 nM in homogenates of NCB-20 cells. The binding of [3H]iloprost to human platelet or NCB-20 cell membranes was inhibited by FCE-22176, and Ki values of 400 and 280 nM were obtained.

Topics: Adenylyl Cyclases; Blood Platelets; Cell Line; Cell Membrane; Enzyme Activation; Epoprostenol; Humans; Iloprost; In Vitro Techniques; Receptors, Epoprostenol; Receptors, Prostaglandin

1986